hCD3EDG/hBCMA(BALB/c)

Fig.1 Detection of hBCMA expression on TACI+CD138+ cells in spleen and bone marrow of WT BALB/c mice and HO hCD3EDG/hBCMA(BALB/c) mice by FACS. Leukocytes were collected from wild-type BALB/c mice (female, 8 weeks old) and homozygous hCD3EDG/hBCMA(BALB/c) humanized mice (female, 7 weeks old), and analyzed by flow cytometry with anti-hBCMA. 

Abbr. HO, homozygous; WT, wild type.

Fig 2. Frequency of leukocyte and myeloid subpopulations in the spleen by flow cytometry

Spleen was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the spleen. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

Fig 3. Frequency of leukocyte and myeloid subpopulations in the BM by flow cytometry

BM was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the BM. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

Fig 4. Frequency of leukocyte and myeloid subpopulations in the blood by flow cytometry

Blood was collected from WT BALB/C mice and HO/HO hCD3EDG/hBCMA(BALB/C) mice (7-week-old, n=3). Flow cytometry analysis of frequencies of (A) lymphocyte and (B) myeloid subpopulations in the blood. Bar indicated expressed as mean ± SEM.

Abbr.  HO/HO, homozygous; WT, wild type.

Table 1. Blood routine examination of hCD3EDG/ hBCMA(BALB/c) knockin mice. Values are expressed as mean±SEM.

Abbr. HO, homozygous; WT, wild type.

Fig 5. In vivo efficacy study of teclistamab in HO hCD3EDG/hBCMA(BALB/c) mice. 

Teclistamab were injected at day 0, 3, 5,  and immune cells in the spleen and bone marrow of mice after therapy were measured by flow cytometry (n=4). Values are shown as mean ± SEM.